LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Status:
Active, not recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of targeted therapies as a possible treatment
for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation
The interventions involved in this study are:
- LY3022855
- Vemurafenib
- Cobimetinib